The Latest Breaking News from gene editing

As any avid gardener will tell you, plants with sharp thorns and prickles can leave you looking like you’ve had a run-in with an angry cat. Wouldn’t it be nice to rid plants of their prickles entirely but keep the tasty fruits and beautiful flowers?

The societal implications of this technology are still vast. And researchers can already start exploring the ethics by engaging communities well ahead of time.

Tuberculosis dates back more than 9,000 years. It is the most infectious bacterial disease and in 2022 10.6 million people fell ill with it. Of these 23% occurred in Africa.

Scientists are pursuing advances to address the technology's limitations and stretch gene editing to treat different types of diseases, improve agriculture, livestock and more.

During her chemistry Nobel Prize lecture in 2018, Frances Arnold said, “Today we can for all practical purposes read, write and edit any sequence of DNA, but we cannot compose it.” That isn’t true anymore.

This article delves into three biotech stocks held in Cathie Wood's ARKK ETF that analysts expect to double in value. Investors looking to add exposure to promising biotech opportunities, with a preference for Wood's disruptive approach to investing, may find these stocks particularly compelling.

The biotechnology industry is thriving, fueled by solid government support, rising healthcare spending worldwide, gene editing breakthroughs, and rapid AI adoption. Hence, fundamentally solid biotech stocks Shionogi (SGIOY), United Therapeutics (UTHR), and SIGA Technologies (SIGA) could be ideal buys for potential gains. Keep reading….

Creating visually distinctive plants likely to become important as more weed-like crops are grown for food

China’s He Jiankui, who used Crispr to edit genome, says he is working on genetic diseases and suggests human embryo gene editing will one day be accepted